Neoadjuvant Nivolumab/Ipilimumab Improves RFS in Stage III Macroscopic Melanoma

Source: OncLive, June 2020

The neoadjuvant combination of nivolumab (Opdivo) and ipilimumab (Yervoy) continued to demonstrate a benefit in relapse-free survival (RFS) compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma, according to 3-year follow-up results of the phase 1b OpACIN trial.1

Updated results of the combination showed that the 3-year RFS rates were 80% versus 60% for patients who received the combination in the neoadjuvant and adjuvant setting versus only the adjuvant setting, respectively. Moreover, at a median follow-up of 36.7 months, the 3-year overall survival (OS) rates were 90% and 70% in the neoadjuvant/adjuvant and adjuvant-only arms, respectively.

Additionally, updated findings from the phase 2 OpACIN-neo trial, which evaluated the optimal dosing schedule of the combination in the neoadjuvant setting for this patient population, showed that at a median follow-up of 17.7 months, relapses were observed in 2% of patients who had a pathologic response to neoadjuvant combination therapy versus 62% of nonresponders.

READ THE ORIGINAL FULL ARTICLE